drugset / Trial / NCT06257693

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

NCT06257693

NaSingle-groupOpen-labelTreatment

Summary

The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.

Timeline

Start
2024-06-21
Primary completion
2028-06-30
Completion
2028-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Enzalutamide Other / unclassified Other